Nature Communications · 2025 · 11 citations · 46 references
Life SciencesInfectious DiseasesPharmacologyApoptosisImmunopathologyInflammationApoptosis In Immune CellsApoptosis PharmacologyApoptotic SignalingBcl-2 Family ProteinsPulmonary TuberculosisTuberculosis PharmacotherapyAnti-apoptotic ProteinsBcl-2 InhibitionBcl-2 Protein ExpressionBcl2 InhibitionFibrosis InhibitionFibrosis ReductionHost-directed TherapyMycobacterium Tuberculosis Infection
Mycobacterium tuberculosis establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue necrosis, fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68+ and CD11b+ cells. Finally, positron emission tomography (PET) in live animals using clinically translatable biomarkers for apoptosis (18F-ICMT-11) and fibrosis (18F-FAPI-74), demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed in postmortem analysis. Our studies suggest that proapoptotic drugs such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis and may be protective against post-TB lung disease. Mycobacterium tuberculosis prevents host-cell apoptosis, causing necrosis and fibrosis, leading to tissue damage. Singh et al. show that strategic targeting of apoptosis with Bcl-2 inhibitors may enhance TB treatments and be protective against post-TB lung disease.
46
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text
Medicine, Oncology, Pharmacology +16
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +14
Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text
Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 818 citations · Full text
Ipr1 gene mediates innate immunity to tuberculosis
Hui Pan, Bo‐Shiun Yan, Mauricio Rojas et al. · Nature · 2005 · 493 citations · Full text